[go: up one dir, main page]

PT2470526E - Compostos e composições como inibidores de proteína quinase - Google Patents

Compostos e composições como inibidores de proteína quinase Download PDF

Info

Publication number
PT2470526E
PT2470526E PT107482119T PT10748211T PT2470526E PT 2470526 E PT2470526 E PT 2470526E PT 107482119 T PT107482119 T PT 107482119T PT 10748211 T PT10748211 T PT 10748211T PT 2470526 E PT2470526 E PT 2470526E
Authority
PT
Portugal
Prior art keywords
compositions
compounds
protein kinase
kinase inhibitors
inhibitors
Prior art date
Application number
PT107482119T
Other languages
English (en)
Inventor
Yongping Xie
Yongqin Wan
Shenlin Huang
Xianming Jin
Zuosheng Liu
Daniel Poon
John TELLEW
Xing Wang
Original Assignee
Novartis Ag
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42782253&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2470526(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Irm Llc filed Critical Novartis Ag
Publication of PT2470526E publication Critical patent/PT2470526E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT107482119T 2009-08-28 2010-08-27 Compostos e composições como inibidores de proteína quinase PT2470526E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23807309P 2009-08-28 2009-08-28
US31303910P 2010-03-11 2010-03-11

Publications (1)

Publication Number Publication Date
PT2470526E true PT2470526E (pt) 2014-09-01

Family

ID=42782253

Family Applications (2)

Application Number Title Priority Date Filing Date
PT141529453T PT2727918T (pt) 2009-08-28 2010-08-27 Compostos e composições como inibidores de proteína quinase
PT107482119T PT2470526E (pt) 2009-08-28 2010-08-27 Compostos e composições como inibidores de proteína quinase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT141529453T PT2727918T (pt) 2009-08-28 2010-08-27 Compostos e composições como inibidores de proteína quinase

Country Status (50)

Country Link
US (12) US8501758B2 (pt)
EP (2) EP2727918B1 (pt)
JP (2) JP5475888B2 (pt)
KR (1) KR101413392B1 (pt)
CN (2) CN103896921B (pt)
AR (1) AR077975A1 (pt)
AU (1) AU2010286569C1 (pt)
BR (1) BR112012004453B1 (pt)
CA (1) CA2771775C (pt)
CL (1) CL2012000340A1 (pt)
CO (1) CO6612222A2 (pt)
CR (1) CR20120102A (pt)
CU (1) CU24110B1 (pt)
CY (3) CY1118452T1 (pt)
DK (2) DK2727918T3 (pt)
DO (1) DOP2012000051A (pt)
EA (2) EA201500175A1 (pt)
EC (2) ECSP12011700A (pt)
ES (2) ES2492499T3 (pt)
GE (1) GEP20146102B (pt)
GT (1) GT201200053A (pt)
HK (1) HK1167390A1 (pt)
HN (1) HN2012000441A (pt)
HR (2) HRP20140799T1 (pt)
HU (3) HUE032847T2 (pt)
IL (1) IL218084A (pt)
IN (1) IN2012DN02469A (pt)
JO (1) JO3002B1 (pt)
LT (3) LT2727918T (pt)
LU (2) LUC00102I2 (pt)
MA (1) MA33604B1 (pt)
ME (2) ME01860B (pt)
MX (1) MX2012002546A (pt)
MY (1) MY156259A (pt)
NI (1) NI201200029A (pt)
NL (1) NL300973I2 (pt)
NO (2) NO2019012I1 (pt)
NZ (1) NZ598924A (pt)
PE (1) PE20120861A1 (pt)
PL (2) PL2470526T3 (pt)
PT (2) PT2727918T (pt)
RS (2) RS53489B1 (pt)
SG (2) SG178351A1 (pt)
SI (2) SI2470526T1 (pt)
SM (3) SMT201700036T1 (pt)
TN (1) TN2012000081A1 (pt)
UA (1) UA112285C2 (pt)
UY (1) UY32860A (pt)
WO (1) WO2011025927A1 (pt)
ZA (1) ZA201202020B (pt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
EP2538943B1 (en) 2010-02-25 2016-03-30 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
US8907270B2 (en) 2010-06-30 2014-12-09 Schlumberger Technology Corporation Method and apparatus for gain regulation in a gamma detector
AU2012335663B2 (en) * 2011-11-11 2015-12-24 Array Biopharma Inc. Method of treating a proliferative disease
PE20141994A1 (es) 2011-11-23 2014-12-24 Novartis Ag Formulaciones farmaceuticas
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CN103159736B (zh) * 2011-12-10 2015-05-13 通化济达医药有限公司 取代的吡唑激酶抑制剂
UY34539A (es) * 2011-12-23 2013-06-28 Millennium Pharm Inc Heteroarilos y usos de los mismos
AU2013240483B2 (en) 2012-03-28 2018-07-26 Dana-Farber Cancer Institute, Inc. C-RAF mutants that confer resistance to RAF inhibitors
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
CA2878469A1 (en) 2012-07-18 2014-01-23 Saint Louis University Beta amino acid derivatives as integrin antagonists
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
EA028420B1 (ru) * 2012-08-07 2017-11-30 Новартис Аг Фармацевтические комбинации, содержащие ингибитор b-raf, ингибитор egfr и, необязательно, ингибитор pi3k-альфа
KR20190057421A (ko) 2012-08-17 2019-05-28 에프. 호프만-라 로슈 아게 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
WO2014047330A1 (en) * 2012-09-19 2014-03-27 Jean-Michel Vernier Novel raf kinase inhibitors
WO2014072493A1 (en) 2012-11-08 2014-05-15 Novartis Ag Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
CN105209073A (zh) 2013-03-21 2015-12-30 诺华股份有限公司 包含B-Raf抑制剂和第二抑制剂的组合疗法
TWI634114B (zh) 2013-05-08 2018-09-01 永恒生物科技公司 作為激酶抑制劑之呋喃酮化合物
MX2015015966A (es) 2013-05-30 2016-04-13 Plexxikon Inc Compuestos para la modulacion de cinasas e indicaciones para los mismos.
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
RU2722784C2 (ru) * 2013-12-20 2020-06-03 Байомед Вэлли Дискавериз, Инк. Лечение злокачественных опухолей с применением комбинаций ингибиторов erk и raf
RU2016129953A (ru) * 2013-12-23 2018-01-30 Новартис Аг Фармацевтические комбинации
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
DE102015103158A1 (de) 2014-03-04 2015-09-10 Bergische Universität Wuppertal Verbindungen für die Behandlung des Melanoms
ME03558B (me) 2014-03-14 2020-07-20 Novartis Ag Molekuli anti-lag-3 antiтela i njihove upotrebe
WO2015145388A2 (en) 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
US10428387B2 (en) 2014-05-16 2019-10-01 University Of Massachusetts Treating chronic myelogenous leukemia (CML)
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
JP6636014B2 (ja) * 2014-09-12 2020-01-29 ノバルティス アーゲー Ｒａｆキナーゼ阻害剤としての化合物および組成物
CN107206071A (zh) 2014-09-13 2017-09-26 诺华股份有限公司 Alk抑制剂的联合疗法
EP3200775B1 (en) 2014-10-03 2019-11-20 Novartis AG Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
UY36351A (es) 2014-10-14 2016-06-01 Novartis Ag Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3317301B1 (en) 2015-07-29 2021-04-07 Novartis AG Combination therapies comprising antibody molecules to lag-3
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
CA3004138A1 (en) 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and tim-3 and their uses
US20180371093A1 (en) 2015-12-17 2018-12-27 Novartis Ag Antibody molecules to pd-1 and uses thereof
ES2806276T3 (es) 2015-12-30 2021-02-17 Univ Saint Louis Derivados de ácido aminobenzoico meta-azaciclicos como antagonistas pan-integrina
RU2615986C1 (ru) * 2016-02-25 2017-04-12 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения
SI3463345T1 (sl) 2016-06-03 2023-02-28 Array Biopharma Inc. Farmacevtski sestavki
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CA3048376A1 (en) * 2016-12-27 2018-07-05 Riken Bmp-signal-inhibiting compound
WO2018146253A1 (en) 2017-02-10 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN107540699A (zh) * 2017-10-16 2018-01-05 康化（上海）新药研发有限公司 一种2‑氨基‑3‑氟吡啶‑4‑硼酸盐酸盐的合成方法
WO2019133810A1 (en) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
CN110256408B (zh) * 2018-07-12 2022-03-22 深圳市塔吉瑞生物医药有限公司 一种二芳基吡唑化合物及包含该化合物的组合物及其用途
WO2020124397A1 (en) * 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. C-terminal src kinase inhibitors
JPWO2020130125A1 (ja) 2018-12-21 2021-11-04 第一三共株式会社 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
CN113811303A (zh) 2019-05-16 2021-12-17 伊莱利利公司 用于治疗brafv600e结直肠癌的erk1/2抑制剂与braf抑制剂和egfr抑制剂的三药组合
CN114746419B (zh) 2019-12-05 2023-10-24 国家医疗保健研究所 N-(3-(5-(嘧啶-4-基)噻唑-4-基)苯基)磺酰胺化合物及其用作braf抑制剂的用途
US20230303551A1 (en) 2020-08-13 2023-09-28 Albert Einstein College Of Medicine N-cyclyl-sulfonamides useful for inhibiting raf
EP4225307A1 (en) 2020-10-05 2023-08-16 Pierre Fabre Medicament Combination of encorafenib and binimetinib as adjuvant treatment for resected stage ii melanoma
JP2024511373A (ja) 2021-03-18 2024-03-13 ノバルティス アーゲー がんのためのバイオマーカーおよびその使用
CN117642166A (zh) 2021-06-09 2024-03-01 中外制药株式会社 用于癌症治疗的组合疗法
CN114181197B (zh) * 2022-02-16 2022-05-06 北京康立生医药技术开发有限公司 一种治疗肠癌的药物的制备方法、制剂及纯度分析方法
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2024163166A1 (en) * 2023-01-30 2024-08-08 5Metis, Inc. Boron containing compounds and their uses
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4104250A (en) * 1976-08-11 1978-08-01 Borg-Warner Corporation Flame-retardant polymers with 1,3,5-triazines having halo- and halo-aryl substitutents
JPS5475888A (en) 1977-11-29 1979-06-18 Jiyasuko Kk Surgical laser
EP0184384B1 (en) 1984-12-06 1989-08-02 Pfizer Inc. Substituted dihydroquinolone carboxylic acids, anti-bacterial compositions containing them
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
EP0952770A4 (en) 1995-09-07 1999-12-22 Fuisz Technologies Ltd SYSTEM FOR MAKING SUBSTANTIALLY NON-SOLUBLE BIOALTERANT AGENTS BIOAVAILABLE
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
EP0910401A1 (en) 1996-05-23 1999-04-28 Applied Research Systems ARS Holdings N.V. Compounds that inhibit the binding of raf-1 or 14-3-3 proteins to the beta chain of il-2 receptor, and pharmaceutical compositions containing same
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
CA2291115A1 (en) 1997-05-22 1998-11-26 G.D. Searle & Co. Substituted pyrazoles as p38 kinase inhibitors
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
ME00275B (me) 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
WO2001047492A1 (en) 1999-12-23 2001-07-05 F H Faulding & Co Limited Improved pharmaceutical compositions for poorly soluble drugs
AU2001285349A1 (en) 2000-08-30 2002-03-13 The Board Of Trustees Of The University Of Arkansas Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
IL161462A0 (en) 2001-10-25 2004-09-27 Novartis Ag Combinations comprising a selective cyclooxygenase-2 inhibitor
DE60222804T2 (de) 2001-12-21 2008-07-03 Vernalis (Cambridge) Ltd., Abington 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung
SI1482932T1 (sl) 2002-03-13 2010-02-26 Array Biopharma Inc N3-alkilirani derivati benzimidazola kot inhibitorji mek
EP1682181A2 (en) 2003-09-23 2006-07-26 Novartis AG Combination of a vegf receptor inhibitor with a chemotherapeutic agent
AU2004289539C1 (en) 2003-11-14 2012-06-07 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
JP2007517825A (ja) 2004-01-09 2007-07-05 ノバルティス アクチエンゲゼルシャフト Ｉｇｆ−ｉｒ阻害剤としてのフェニル−［４−（３−フェニル−１ｈ−ピラゾル−４−イル）−ピリミジン−２−イル］−アミン誘導体
MXPA06014247A (es) 2004-06-10 2007-03-12 Irm Llc Compuestos y composiciones como inhibidores de la proteina quinasa.
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
MX2007011435A (es) 2005-03-17 2007-12-05 Novartis Ag N-[3-(1-amino-5,6,7,8-tetrahidro-2,4,4b-triazafluoren-9-il)-fenil ]-benzamidas como inhibidores de cinasa de tirosina/treonina, en particular de cinasa b-raf.
US20070099856A1 (en) 2005-05-13 2007-05-03 Gumerlock Paul H Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen
CA2618377A1 (en) 2005-08-12 2007-02-22 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate hsp90 activity
US20090214645A1 (en) 2005-08-22 2009-08-27 Andrea Kramer Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent
EP1917258A2 (en) 2005-08-26 2008-05-07 SmithKline Beecham Corporation Pyrimidinyl-pyrazole inhibitors of aurora kinases
PE20070427A1 (es) 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
WO2007105058A2 (en) 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
AU2007234379A1 (en) 2006-04-05 2007-10-11 Novartis Ag. Combinations of therapeutic agents for treating cancer
EP2013218A2 (en) * 2006-04-17 2009-01-14 Arqule, Inc. Raf inhibitors and their uses
JP2010502743A (ja) 2006-09-11 2010-01-28 キュリス，インコーポレイテッド 抗増殖薬剤としての多機能性低分子
ES2385613T3 (es) 2006-09-18 2012-07-27 Boehringer Ingelheim International Gmbh Método para tratar cánceres que portan mutaciones de EGFR
CN103739595A (zh) 2006-10-02 2014-04-23 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
WO2008045627A2 (en) * 2006-10-06 2008-04-17 Irm Llc Protein kinase inhibitors and methods for using thereof
JP2010519209A (ja) 2007-02-15 2010-06-03 ノバルティス アーゲー 癌を処置するためのｌｂｈ５８９と他の治療剤の組み合わせ剤
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
EA201000113A1 (ru) * 2007-08-01 2010-08-30 Пфайзер Инк. Пиразольные соединения
RU2010119929A (ru) 2007-10-19 2011-11-27 Эбботт Гмбх Унд Ко.Кг (De) Твердый дисперсный продукт лекарственных средств на основе n-арилмочевины
WO2009062676A2 (en) 2007-11-14 2009-05-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
BRPI0908906A2 (pt) * 2008-03-21 2019-09-24 Novartis Ag compostos heterocíclicos e usos dos mesmos
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CN102105459B (zh) 2008-07-24 2014-09-10 内尔维阿诺医学科学有限公司 作为蛋白激酶抑制剂的3,4-二芳基吡唑类
BRPI0916713A2 (pt) 2008-07-28 2015-11-10 Gilead Science Inc compostos inibidores de histona desacetilase de cicloalquilideno e heterocicloalquilideno
WO2010034838A2 (en) 2008-09-29 2010-04-01 Boehringer Ingelheim International Gmbh New chemical compounds
PT2346495T (pt) 2008-10-07 2016-11-11 Astrazeneca Uk Ltd Formulação farmacêutica 514
WO2010056662A1 (en) * 2008-11-11 2010-05-20 University Of Washington Activated wnt-beta-catenin signaling in melanoma
EP2373664B1 (en) 2008-12-19 2013-06-12 Nerviano Medical Sciences S.r.l. Bicyclic pyrazoles as protein kinase inhibitors
AR075180A1 (es) 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
RU2402602C1 (ru) 2009-02-12 2010-10-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
EP2443117B1 (en) * 2009-06-15 2016-03-23 Nerviano Medical Sciences S.r.l. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
KR101256018B1 (ko) * 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
US8242260B2 (en) * 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
AU2011209234B2 (en) 2010-01-27 2015-05-07 Nerviano Medical Sciences S.R.L. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
AU2011238616B2 (en) 2010-03-30 2016-08-04 Verseon Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
CN103153980B (zh) 2010-08-03 2015-12-16 内尔维安诺医学科学有限公司 吡唑并苯基苯磺酰胺化合物的衍生物及其作为抗肿瘤药的用途
KR101909313B1 (ko) 2011-03-21 2018-10-17 발큐리아 에이비 Hdac 저해제 및 스테로이드를 포함하는 약학적 조성물 및 이의 용도
NZ618367A (en) 2011-06-14 2016-01-29 Novartis Ag Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
AU2012335663B2 (en) 2011-11-11 2015-12-24 Array Biopharma Inc. Method of treating a proliferative disease
PE20141994A1 (es) 2011-11-23 2014-12-24 Novartis Ag Formulaciones farmaceuticas
WO2014072493A1 (en) 2012-11-08 2014-05-15 Novartis Ag Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
US10576680B2 (en) 2015-11-19 2020-03-03 The Boeing Company Modular thermoforming system

Also Published As

Publication number Publication date
ECSP23004573A (es) 2023-04-28
LUC00101I2 (pt) 2020-01-23
JO3002B1 (ar) 2016-09-05
IN2012DN02469A (pt) 2015-08-21
PL2727918T3 (pl) 2017-06-30
US9593099B2 (en) 2017-03-14
WO2011025927A1 (en) 2011-03-03
AU2010286569C1 (en) 2019-11-28
PT2727918T (pt) 2017-01-20
DOP2012000051A (es) 2012-05-31
US20160120866A1 (en) 2016-05-05
US9850229B2 (en) 2017-12-26
CN102725283A (zh) 2012-10-10
JP5475888B2 (ja) 2014-04-16
CR20120102A (es) 2012-05-02
EP2470526A1 (en) 2012-07-04
US9593100B2 (en) 2017-03-14
SG178351A1 (en) 2012-03-29
DK2470526T3 (da) 2014-08-25
MY156259A (en) 2016-01-29
SMT201700036B (it) 2017-03-08
US20160263113A1 (en) 2016-09-15
PL2470526T3 (pl) 2014-10-31
MA33604B1 (fr) 2012-09-01
US20200323852A1 (en) 2020-10-15
PE20120861A1 (es) 2012-07-14
GT201200053A (es) 2014-03-27
ES2492499T3 (es) 2014-09-09
NO2019011I1 (no) 2019-03-05
CA2771775C (en) 2015-01-20
SI2470526T1 (sl) 2014-09-30
US8501758B2 (en) 2013-08-06
CY2019013I2 (el) 2019-11-27
AR077975A1 (es) 2011-10-05
HUS1900013I1 (hu) 2019-04-29
US20160280686A1 (en) 2016-09-29
USRE49556E1 (en) 2023-06-20
US9850230B2 (en) 2017-12-26
SMT201700036T1 (it) 2017-03-08
EP2727918A1 (en) 2014-05-07
CU20120034A7 (es) 2012-06-21
US20180297986A1 (en) 2018-10-18
US10005761B2 (en) 2018-06-26
UY32860A (es) 2011-03-31
US20180297985A1 (en) 2018-10-18
SG10201405311TA (en) 2014-09-26
AU2010286569B2 (en) 2013-10-10
US10568884B2 (en) 2020-02-25
US20130296318A1 (en) 2013-11-07
CL2012000340A1 (es) 2012-08-17
ME02684B (me) 2017-06-20
EA201200373A1 (ru) 2012-09-28
US20230116233A1 (en) 2023-04-13
NO2019012I1 (no) 2019-03-05
ME01860B (me) 2014-12-20
CN103896921A (zh) 2014-07-02
GEP20146102B (en) 2014-05-27
US9314464B2 (en) 2016-04-19
NI201200029A (es) 2012-05-29
HUE032847T2 (hu) 2017-11-28
SMT201400133B (it) 2014-11-10
CY2019013I1 (el) 2019-11-27
EA201500175A1 (ru) 2015-05-29
UA112285C2 (uk) 2016-08-25
LUC00101I1 (pt) 2019-02-13
RS55568B1 (sr) 2017-05-31
LT2727918T (lt) 2017-01-25
HK1167390A1 (en) 2012-11-30
HN2012000441A (es) 2015-01-05
CU24110B1 (es) 2015-07-30
IL218084A (en) 2016-11-30
JP2013503186A (ja) 2013-01-31
HRP20140799T1 (hr) 2014-11-07
JP2014098022A (ja) 2014-05-29
CY2019014I1 (el) 2019-11-27
CY1118452T1 (el) 2017-07-12
CO6612222A2 (es) 2013-02-01
EA025222B1 (ru) 2016-12-30
HUS1900012I1 (hu) 2019-04-29
NL300973I1 (pt) 2019-03-27
ECSP12011700A (es) 2012-03-30
RS53489B1 (en) 2015-02-27
ZA201202020B (en) 2012-12-27
KR20120062839A (ko) 2012-06-14
BR112012004453A2 (pt) 2021-03-09
DK2727918T3 (da) 2017-01-23
LTPA2019005I1 (lt) 2019-03-25
AU2010286569A1 (en) 2012-04-12
LUC00102I2 (pt) 2024-05-21
TN2012000081A1 (en) 2013-09-19
LTPA2019006I1 (lt) 2019-03-25
US20160122324A1 (en) 2016-05-05
BR112012004453A8 (pt) 2021-06-08
IL218084A0 (en) 2012-04-30
MX2012002546A (es) 2012-04-11
HRP20170005T1 (hr) 2017-03-10
CA2771775A1 (en) 2011-03-03
CY2019014I2 (el) 2019-11-27
BR112012004453B1 (pt) 2022-04-26
SI2727918T1 (sl) 2017-02-28
LTC2470526I2 (lt) 2020-04-27
ES2610825T3 (es) 2017-05-03
JP6045519B2 (ja) 2016-12-14
US20160280687A1 (en) 2016-09-29
NZ598924A (en) 2013-07-26
CN103896921B (zh) 2016-02-24
KR101413392B1 (ko) 2014-06-27
EP2727918B1 (en) 2016-10-12
CN102725283B (zh) 2014-02-26
US20110306625A1 (en) 2011-12-15
EP2470526B1 (en) 2014-05-28
US10576080B2 (en) 2020-03-03
NL300973I2 (nl) 2022-05-05

Similar Documents

Publication Publication Date Title
LTPA2019006I1 (lt) Junginiai ir kompozicijos kaip proteinkinazės inhibitoriai
PT2470528E (pt) Compostos e composições como inibidores de proteína quinase
HUS1900014I1 (hu) Proteinkináz inhibitorok
HRP20130698T1 (en) Novel phenylpyrazinones as kinase inhibitors
IL206416A0 (en) Benzofuropyrimidinones as protein kinase inhibitors
PT2200436E (pt) Pirimidinilaminas substituídas como inibidoras da proteína quinase
HRP20130787T1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
SI2193133T1 (sl) Imidazolotiadiazoli za uporabo kot zaviralci protein-kinaze
IL210073A0 (en) Protein kinase inhibitors
EP2387572A4 (en) PROTEIN KINASE C HEMMER AND ITS USE
IL210069A0 (en) Protein kinase inhibitors
HK1156306A1 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases hif--4-
EP2231152A4 (en) THIENOPYRANONES AS KINASE INHIBITORS
GB0807642D0 (en) IKK- serine-threonine protein kinase inhibitors